Message #14 From:
NewsBot Date: June 29, 2006 06:15:00 AM
CYGX News CytoGenix Receives the 2006 Frost & Sullivan Technology Innovation Award for synDNA(TM)
HOUSTON--(BUSINESS WIRE)--June 29, 2006--CytoGenix, Inc. (OTCBB:CYGX) Frost & Sullivan, the leading global growth consulting company has chosen CytoGenix as the recipient of the 2006 Technology Innovation Award in biotechnology processing for the development of the synDNA(TM) large-scale DNA production technology.
To identify the award recipient, Frost and Sullivan's analyst team tracks innovation in key hi-tech markets. The selection process includes extensive primary and secondary research. In addition to the research methodology, the recipient must excel based on measurement criteria such as significance of the innovation in the industry, potential of the innovation to become the industry standard, competitive advantage, impact on company bottom-line and breadth of intellectual property and peer-reviewed scientific publication.
Dr. Malcolm Skolnick, CytoGenix, Inc. CEO, states, "Frost and Sullivan is the premium firm in biosciences market research with over forty years of experience in hi-tech markets. CytoGenix' synDNA(TM) has been selected as the best-in-class innovation in recognition of its revolutionary potential for changing DNA manufacture. Our technology will make DNA medicines such as vaccines readily available and accessible worldwide. Our short term goal is to develop synDNA(TM) vaccines including Avian Flu, small pox and Brucellosis as well as contract manufacturing of synDNA(TM) for other biotechnology companies."
About CytoGenix, Inc.
CytoGenix, Inc. is a Houston-based biopharmaceutical company that develops and markets innovative products and services based on its proprietary ssDNA expression technology. The company has developed a breakthrough synthetic process for large-scale production of high purity DNA at a fraction of the cost of traditional fermentation methods. CytoGenix currently has one issued US patent and 47 international or US pending patent applications claiming methods and materials in connection with this platform technology.
About Frost & Sullivan
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.awards.frost.com or http://www.healthcare.frost.com
SAFE HARBOR: Except for statements of historical fact, the statements in this press release are forward-looking. Such statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include, but are not limited to, general economic conditions, risks associated with the acceptance of new products, competition, and other factors more fully detailed in the company's filings with the Securities and Exchange Commission. Additional information about CytoGenix and its technology is found on the website at www.cytogenix.com.
